Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma

Autor: Rossi, Cédric, Tosolini, Marie, Gravelle, Pauline, Pericart, Sarah, Kanoun, Salim, Evrard, Solene, Gilhodes, Julia, Franchini, Don-Marc, Amara, Nadia, Syrykh, Charlotte, Bories, Pierre, Oberic, Lucie, Ysebaert, Loïc, Martin, Laurent, Ramla, Selim, Robert, Philippine, Tabouret-Viaud, Claire, Casasnovas, René-Olivier, Fournié, Jean-Jacques, Bezombes, Christine, Laurent, Camille

Publikováno v: Haematologica
Haematologica, Ferrata Storti Foundation, 2020, ⟨10.3324/haematol.2020.263194⟩

Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate positron emission tomog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::322e6107be4a64eeb6c98f2648b7c982
https://hal.archives-ouvertes.fr/hal-03365480

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.

Autor: Chevreux S; Department of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.; INSERM, Unit 1231, University of Burgundy Franche-Comté, 21078 Dijon, France., de Barros S; Department of Hematology, University Institute of Cancer Toulouse-Oncopole, 31100 Toulouse, France., Laurent C; Department of Pathology, University Institute du Cancer, Toulouse University Hospital, 31300 Toulouse, France.; INSERM, Unit 1037, Cancer Research Center of Toulouse-Purpan, Laboratoire D'excellence TOUCAN, 31037 Toulouse, France., Durand A; Department of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.; INSERM, Unit 1231, University of Burgundy Franche-Comté, 21078 Dijon, France., Delpierre C; Department of Hematology, University Institute of Cancer Toulouse-Oncopole, 31100 Toulouse, France., Robert P; Department of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.; INSERM, Unit 1231, University of Burgundy Franche-Comté, 21078 Dijon, France., Joubert C; Lymphoma Academic Research Organisation, CHU Lyon-Sud, 69495 Lyon, France., Griolet S; Lymphoma Academic Research Organisation, CHU Lyon-Sud, 69495 Lyon, France., Kanoun S; Nuclear Medicine Unit, Institut Universitaire du Cancer Toulouse-Oncopole, 31100 Toulouse, France., Bastie JN; Department of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.; INSERM, Unit 1231, University of Burgundy Franche-Comté, 21078 Dijon, France., Casasnovas RO; Department of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.; INSERM, Unit 1231, University of Burgundy Franche-Comté, 21078 Dijon, France., Rossi C; Department of Hematology, Dijon-Bourgogne University Hospital, 21000 Dijon, France.; INSERM, Unit 1231, University of Burgundy Franche-Comté, 21078 Dijon, France.; Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA 94305-5458, USA.

Publikováno v: Cancers [Cancers (Basel)] 2022 Dec 22; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 22.